PortalPublikationenCrooke Cell Adenoma Confers Poorer Endocrinological Outcomes...

Crooke Cell Adenoma Confers Poorer Endocrinological Outcomes Compared with Corticotroph Adenoma: Results of a Multicenter, International Analysis

Standard

Crooke Cell Adenoma Confers Poorer Endocrinological Outcomes Compared with Corticotroph Adenoma: Results of a Multicenter, International Analysis. / Findlay, Matthew C; Drexler, Richard; Azab, Mohammed; Karbe, Arian; Rotermund, Roman; Ricklefs, Franz L; Flitsch, Jörg; Smith, Timothy R; Kilgallon, John L; Honegger, Jürgen; Nasi-Kordhishti, Isabella; Gardner, Paul A; Gersey, Zachary C; Abdallah, Hussein M; Jane, John A; Marino, Alexandria C; Knappe, Ulrich J; Uksul, Nesrin; Rzaev, Jamil A; Bervitskiy, Anatoliy V; Schroeder, Henry W S; Eördögh, Márton; Losa, Marco; Mortini, Pietro; Gerlach, Rüdiger; Antunes, Apio C M; Couldwell, William T; Budohoski, Karol P; Rennert, Robert C; Karsy, Michael.

in: WORLD NEUROSURG, Jahrgang 180, 12.2023, S. e376-e391.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Findlay, MC, Drexler, R, Azab, M, Karbe, A, Rotermund, R, Ricklefs, FL, Flitsch, J, Smith, TR, Kilgallon, JL, Honegger, J, Nasi-Kordhishti, I, Gardner, PA, Gersey, ZC, Abdallah, HM, Jane, JA, Marino, AC, Knappe, UJ, Uksul, N, Rzaev, JA, Bervitskiy, AV, Schroeder, HWS, Eördögh, M, Losa, M, Mortini, P, Gerlach, R, Antunes, ACM, Couldwell, WT, Budohoski, KP, Rennert, RC & Karsy, M 2023, 'Crooke Cell Adenoma Confers Poorer Endocrinological Outcomes Compared with Corticotroph Adenoma: Results of a Multicenter, International Analysis', WORLD NEUROSURG, Jg. 180, S. e376-e391. https://doi.org/10.1016/j.wneu.2023.09.076

APA

Findlay, M. C., Drexler, R., Azab, M., Karbe, A., Rotermund, R., Ricklefs, F. L., Flitsch, J., Smith, T. R., Kilgallon, J. L., Honegger, J., Nasi-Kordhishti, I., Gardner, P. A., Gersey, Z. C., Abdallah, H. M., Jane, J. A., Marino, A. C., Knappe, U. J., Uksul, N., Rzaev, J. A., ... Karsy, M. (2023). Crooke Cell Adenoma Confers Poorer Endocrinological Outcomes Compared with Corticotroph Adenoma: Results of a Multicenter, International Analysis. WORLD NEUROSURG, 180, e376-e391. https://doi.org/10.1016/j.wneu.2023.09.076

Vancouver

Findlay MC, Drexler R, Azab M, Karbe A, Rotermund R, Ricklefs FL et al. Crooke Cell Adenoma Confers Poorer Endocrinological Outcomes Compared with Corticotroph Adenoma: Results of a Multicenter, International Analysis. WORLD NEUROSURG. 2023 Dez;180:e376-e391. https://doi.org/10.1016/j.wneu.2023.09.076

Bibtex

@article{b9170283742a49b99d61baa9930b13d7,
title = "Crooke Cell Adenoma Confers Poorer Endocrinological Outcomes Compared with Corticotroph Adenoma: Results of a Multicenter, International Analysis",
abstract = "BACKGROUND: Crooke cell adenomas (CCAs) are a rare, aggressive subset of secretory pituitary corticotroph adenomas (sCTAs) found in 5%-10% of patients with Cushing disease. Multiple studies support worse outcomes in CCAs but are limited by small sample size and single-institution databases. We compared outcomes in CCA and sCTA using a multicenter, international retrospective database of high-volume skull base centers.METHODS: Patients surgically treated for pituitary adenoma from January 2017 through December 2020 were included.RESULTS: Among 2826 patients from 12 international centers, 20 patients with CCA and 480 patients with sCTA were identified. No difference in baseline demographics, tumor characteristics, or postoperative complications was seen. Microsurgical approaches (60% CCA vs. 62.3% sCTA) were most common. Gross total resection was higher in CCA patients (100% vs. 83%, P = 0.05). Among patients with gross total resection according to intraoperative findings, fewer CCA patients had postoperative hormone normalization of pituitary function (50% vs. 77.8%, P < 0.01) and remission of hypersecretion by 3-6 months (75% vs. 84.3%, P < 0.01). This was the case despite CCA having better local control rates (100% vs. 96%, P < 0.01) and fewer patients with remnant on magnetic resonance imaging (0% vs. 7.2%, P < 0.01). A systematic literature review of 35 studies reporting on various treatment strategies reiterated the high rate of residual tumor, persistent hypercortisolism, and tumor-related mortality in CCA patients.CONCLUSIONS: This modern, multicenter series of patients with CCA reflects their poor prognosis and reduced postsurgical hormonal normalization. Further work is necessary to better understand the pathophysiology of CCA to devise more targeted treatment approaches.",
author = "Findlay, {Matthew C} and Richard Drexler and Mohammed Azab and Arian Karbe and Roman Rotermund and Ricklefs, {Franz L} and J{\"o}rg Flitsch and Smith, {Timothy R} and Kilgallon, {John L} and J{\"u}rgen Honegger and Isabella Nasi-Kordhishti and Gardner, {Paul A} and Gersey, {Zachary C} and Abdallah, {Hussein M} and Jane, {John A} and Marino, {Alexandria C} and Knappe, {Ulrich J} and Nesrin Uksul and Rzaev, {Jamil A} and Bervitskiy, {Anatoliy V} and Schroeder, {Henry W S} and M{\'a}rton E{\"o}rd{\"o}gh and Marco Losa and Pietro Mortini and R{\"u}diger Gerlach and Antunes, {Apio C M} and Couldwell, {William T} and Budohoski, {Karol P} and Rennert, {Robert C} and Michael Karsy",
note = "Copyright {\textcopyright} 2023 Elsevier Inc. All rights reserved.",
year = "2023",
month = dec,
doi = "10.1016/j.wneu.2023.09.076",
language = "English",
volume = "180",
pages = "e376--e391",
journal = "WORLD NEUROSURG",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Crooke Cell Adenoma Confers Poorer Endocrinological Outcomes Compared with Corticotroph Adenoma: Results of a Multicenter, International Analysis

AU - Findlay, Matthew C

AU - Drexler, Richard

AU - Azab, Mohammed

AU - Karbe, Arian

AU - Rotermund, Roman

AU - Ricklefs, Franz L

AU - Flitsch, Jörg

AU - Smith, Timothy R

AU - Kilgallon, John L

AU - Honegger, Jürgen

AU - Nasi-Kordhishti, Isabella

AU - Gardner, Paul A

AU - Gersey, Zachary C

AU - Abdallah, Hussein M

AU - Jane, John A

AU - Marino, Alexandria C

AU - Knappe, Ulrich J

AU - Uksul, Nesrin

AU - Rzaev, Jamil A

AU - Bervitskiy, Anatoliy V

AU - Schroeder, Henry W S

AU - Eördögh, Márton

AU - Losa, Marco

AU - Mortini, Pietro

AU - Gerlach, Rüdiger

AU - Antunes, Apio C M

AU - Couldwell, William T

AU - Budohoski, Karol P

AU - Rennert, Robert C

AU - Karsy, Michael

N1 - Copyright © 2023 Elsevier Inc. All rights reserved.

PY - 2023/12

Y1 - 2023/12

N2 - BACKGROUND: Crooke cell adenomas (CCAs) are a rare, aggressive subset of secretory pituitary corticotroph adenomas (sCTAs) found in 5%-10% of patients with Cushing disease. Multiple studies support worse outcomes in CCAs but are limited by small sample size and single-institution databases. We compared outcomes in CCA and sCTA using a multicenter, international retrospective database of high-volume skull base centers.METHODS: Patients surgically treated for pituitary adenoma from January 2017 through December 2020 were included.RESULTS: Among 2826 patients from 12 international centers, 20 patients with CCA and 480 patients with sCTA were identified. No difference in baseline demographics, tumor characteristics, or postoperative complications was seen. Microsurgical approaches (60% CCA vs. 62.3% sCTA) were most common. Gross total resection was higher in CCA patients (100% vs. 83%, P = 0.05). Among patients with gross total resection according to intraoperative findings, fewer CCA patients had postoperative hormone normalization of pituitary function (50% vs. 77.8%, P < 0.01) and remission of hypersecretion by 3-6 months (75% vs. 84.3%, P < 0.01). This was the case despite CCA having better local control rates (100% vs. 96%, P < 0.01) and fewer patients with remnant on magnetic resonance imaging (0% vs. 7.2%, P < 0.01). A systematic literature review of 35 studies reporting on various treatment strategies reiterated the high rate of residual tumor, persistent hypercortisolism, and tumor-related mortality in CCA patients.CONCLUSIONS: This modern, multicenter series of patients with CCA reflects their poor prognosis and reduced postsurgical hormonal normalization. Further work is necessary to better understand the pathophysiology of CCA to devise more targeted treatment approaches.

AB - BACKGROUND: Crooke cell adenomas (CCAs) are a rare, aggressive subset of secretory pituitary corticotroph adenomas (sCTAs) found in 5%-10% of patients with Cushing disease. Multiple studies support worse outcomes in CCAs but are limited by small sample size and single-institution databases. We compared outcomes in CCA and sCTA using a multicenter, international retrospective database of high-volume skull base centers.METHODS: Patients surgically treated for pituitary adenoma from January 2017 through December 2020 were included.RESULTS: Among 2826 patients from 12 international centers, 20 patients with CCA and 480 patients with sCTA were identified. No difference in baseline demographics, tumor characteristics, or postoperative complications was seen. Microsurgical approaches (60% CCA vs. 62.3% sCTA) were most common. Gross total resection was higher in CCA patients (100% vs. 83%, P = 0.05). Among patients with gross total resection according to intraoperative findings, fewer CCA patients had postoperative hormone normalization of pituitary function (50% vs. 77.8%, P < 0.01) and remission of hypersecretion by 3-6 months (75% vs. 84.3%, P < 0.01). This was the case despite CCA having better local control rates (100% vs. 96%, P < 0.01) and fewer patients with remnant on magnetic resonance imaging (0% vs. 7.2%, P < 0.01). A systematic literature review of 35 studies reporting on various treatment strategies reiterated the high rate of residual tumor, persistent hypercortisolism, and tumor-related mortality in CCA patients.CONCLUSIONS: This modern, multicenter series of patients with CCA reflects their poor prognosis and reduced postsurgical hormonal normalization. Further work is necessary to better understand the pathophysiology of CCA to devise more targeted treatment approaches.

U2 - 10.1016/j.wneu.2023.09.076

DO - 10.1016/j.wneu.2023.09.076

M3 - SCORING: Journal article

C2 - 37757948

VL - 180

SP - e376-e391

JO - WORLD NEUROSURG

JF - WORLD NEUROSURG

SN - 1878-8750

ER -